Biotech's bad boy takes stake in 'liquidating' KaloBios, stock soars 400%

Martin Shkreli is riding KaloBios Pharmaceuticals Inc. to its end or a new beginning. The drug company CEO and investor — best known for a 5,000-plus percent price hike of a generic drug by his Turing Pharmaceuticals Inc...